Fig. 4

Representative images of the tumor immune microenvironment at lung metastatic sites in advanced-stage mRCC model mice treated with vehicle (control), JX-594, PD-1 inhibitor, PD-1 and CTLA-4 inhibitor combination, and JX-594 and PD-1 inhibitor combination. Tumor sections were stained for CD8⁺ cytotoxic T cells, CD31⁺ blood vessel, PD-L1⁺CK⁺ immune checkpoints in tumor cells, Gr1⁺CD11b⁺ myeloid cells, F4/80⁺iNOS⁺ M1 tumor-associated macrophages (TAMs), F4/80⁺CD206⁺ M2 TAMs, CD4⁺FOXP3⁺ regulatory T cells